Innovating on Inhaled Bioequivalence: A Critical Analysis of the Current Limitations, Potential Solutions and Stakeholders of the Process

Orally inhaled drug products (OIDPs) are an important group of medicines traditionally used to treat pulmonary diseases. Over the past decade, this trend has broadened, increasing their use in other conditions such as diabetes, expanding the interest in this administration route. Thus, the bioequiva...

Descripción completa

Detalles Bibliográficos
Autores principales: Gallegos-Catalán, Jonattan, Warnken, Zachary, Bahamondez-Canas, Tania F., Moraga-Espinoza, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8309038/
https://www.ncbi.nlm.nih.gov/pubmed/34371741
http://dx.doi.org/10.3390/pharmaceutics13071051

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8309038/
https://www.ncbi.nlm.nih.gov/pubmed/34371741
http://dx.doi.org/10.3390/pharmaceutics13071051

Ejemplares similares